Clinical Trial Detail

NCT ID	NCT03175224
Title	CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation
Recruitment	Recruiting
Gender
Phase	Phase I
Variant Requirements	yes
Sponsors	CBT Pharmaceuticals, Inc.
Indications	renal cell carcinoma gastroesophageal junction adenocarcinoma stomach carcinoma Advanced Solid Tumor non-small cell lung carcinoma
Therapies	CBT-101
Age Groups: